CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 89,132	$ 113,915
Research supplies	57,785	114,225
Grant funds receivable	37,562	11,438
Receivables for Development Agreement	0	5,990
Prepaid expenses and other current assets	64,543	17,691
Total current assets	249,022	263,259
Property and equipment, net	4,929	7,053
Total Assets	253,951	270,312
CURRENT LIABILITIES
Accounts payable and accrued liabilities	127,217	222,704
Deferred revenues	0	82,553
Total current liabilities	127,217	305,257
LONG TERM LIABILITIES
Accrued licensing fees	652,359	682,833
Other liabilities	145,396	148,019
Total long term liabilities	797,755	830,852
Total liabilities	924,972	1,136,109
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS' DEFICIT
Common stock, par value $0.001 per share; 300,000,000 shares authorized; 24,379,350 and 23,879,350 shares issued and outstanding at December 31, 2018 and 2017, respectively	24,380	23,880
Additional paid-in capital	9,144,464	8,988,125
Accumulated other comprehensive loss	(31,231)	(29,827)
Accumulated deficit	(9,812,564)	(9,848,699)
Total Proteo, Inc. Stockholders' Deficit	(674,127)	(865,797)
Noncontrolling Interest	3,106	0
Total stockholders' deficit	(671,021)	(865,797)
Total liabilities and stockholders' deficit	253,951	270,312
Series A Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Non-voting preferred stock, par value $0.001 per share; 10,000,000 shares authorized; Series A, 723,590 shares issued and outstanding; Series B-1, 100,000 and 0 shares issued and outstanding at December 31, 2018 and 2017, respectively	724	724
Series B Preferred Stock [Member]
STOCKHOLDERS' DEFICIT
Non-voting preferred stock, par value $0.001 per share; 10,000,000 shares authorized; Series A, 723,590 shares issued and outstanding; Series B-1, 100,000 and 0 shares issued and outstanding at December 31, 2018 and 2017, respectively	$ 100	$ 0